PE20130813A1 - Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmaceuticas que la contienen - Google Patents
Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmaceuticas que la contienenInfo
- Publication number
- PE20130813A1 PE20130813A1 PE2012002234A PE2012002234A PE20130813A1 PE 20130813 A1 PE20130813 A1 PE 20130813A1 PE 2012002234 A PE2012002234 A PE 2012002234A PE 2012002234 A PE2012002234 A PE 2012002234A PE 20130813 A1 PE20130813 A1 PE 20130813A1
- Authority
- PE
- Peru
- Prior art keywords
- propoxi
- hexahydrocyclopenta
- benzamide
- antagonist
- cis
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000848 glutamatergic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003891 oxalate salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) EL COMPUESTO 4-{3-[CIS-HEXAHIDROCICLOPENTA[c]PIRROL-2(1H)-IL]PROPOXI}BENZAMIDA DE FORMULA (I) EN LA FORMA DE UN OXALATO O UN HIDROCLORURO Y EN UNA CANTIDAD DE 2MG, 5MG O 20MG; Y B) UN ANTAGONISTA DE LOS RECEPTORES GLUTAMATERGICOS NMDA TAL COMO MEMANTINA EN FORMA DE HIDROCLORURO Y EN UNA CANTIDAD DE 10MG O 20MG. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LOS TRASTORNOS COGNITIVOS ASOCIADOS A LA ENFERMEDAD DE ALZHEIMER
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161568831P | 2011-12-09 | 2011-12-09 | |
| FR1103777A FR2983732B1 (fr) | 2011-12-09 | 2011-12-09 | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130813A1 true PE20130813A1 (es) | 2013-07-28 |
Family
ID=47682151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002234A PE20130813A1 (es) | 2011-12-09 | 2012-11-28 | Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmaceuticas que la contienen |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8921409B2 (es) |
| EP (1) | EP2601942A1 (es) |
| JP (1) | JP5591310B2 (es) |
| KR (1) | KR101489670B1 (es) |
| CN (1) | CN103157111B (es) |
| AP (1) | AP3225A (es) |
| AR (1) | AR089112A1 (es) |
| AU (1) | AU2012258339A1 (es) |
| BR (1) | BR102012031031A2 (es) |
| CA (1) | CA2798549A1 (es) |
| CL (1) | CL2012003437A1 (es) |
| CO (2) | CO6660080A1 (es) |
| CR (1) | CR20120608A (es) |
| EA (1) | EA201201530A1 (es) |
| EC (1) | ECSP12012329A (es) |
| FR (1) | FR2983732B1 (es) |
| GT (1) | GT201200329A (es) |
| MA (1) | MA34867B1 (es) |
| MD (1) | MD4348B1 (es) |
| MX (1) | MX2012014184A (es) |
| NI (1) | NI201200178A (es) |
| PE (1) | PE20130813A1 (es) |
| PH (1) | PH12012000378A1 (es) |
| SG (1) | SG191494A1 (es) |
| TN (1) | TN2012000563A1 (es) |
| TW (1) | TWI457123B (es) |
| UY (1) | UY34475A (es) |
| WO (1) | WO2013083887A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3003466B1 (fr) * | 2013-03-22 | 2015-08-07 | Servier Lab | Utilisation du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide pour le traitement des douleurs neuropathiques |
| KR101484405B1 (ko) * | 2013-08-14 | 2015-01-19 | 서울대학교산학협력단 | Ｎｉｎｊｕｒｉｎ１ 결핍 유래의 강박증 예방 또는 치료용 약학적 조성물 |
| GB201509134D0 (en) * | 2015-05-28 | 2015-07-15 | Electrophoretics Ltd | Biomolecules involved in Alzheimer's disease |
| JP7429942B2 (ja) | 2015-07-22 | 2024-02-09 | アナベックス ライフ サイエンシズ コーポレイション | テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60324788D1 (de) * | 2002-05-31 | 2009-01-02 | Lundbeck & Co As H | Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit |
| AU2004251636B2 (en) * | 2003-05-27 | 2006-11-09 | Merz Pharma Gmbh & Co. Kgaa | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
| WO2005000305A1 (en) * | 2003-06-20 | 2005-01-06 | Eli Lilly And Company | 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake |
| ATE486592T1 (de) * | 2004-01-05 | 2010-11-15 | Merz Pharma Gmbh & Co Kgaa | Memantin für die behandlung von leichtem bis mittelschwerem morbus alzheimer |
| FR2866647B1 (fr) * | 2004-02-20 | 2006-10-27 | Servier Lab | Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
| WO2005092009A2 (en) * | 2004-03-19 | 2005-10-06 | Axonyx, Inc. | Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders |
| FR2937119B1 (fr) | 2008-10-15 | 2010-12-17 | Air Liquide | Procede de production d'energie et capture de co2 |
| FR2937251B1 (fr) * | 2008-10-16 | 2011-03-18 | Servier Lab | Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil |
| FR2953515B1 (fr) * | 2009-12-09 | 2011-12-23 | Servier Lab | Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2011
- 2011-12-09 FR FR1103777A patent/FR2983732B1/fr not_active Expired - Fee Related
-
2012
- 2012-04-27 CO CO12069442A patent/CO6660080A1/es unknown
- 2012-11-28 AU AU2012258339A patent/AU2012258339A1/en not_active Abandoned
- 2012-11-28 UY UY0001034475A patent/UY34475A/es unknown
- 2012-11-28 PE PE2012002234A patent/PE20130813A1/es not_active Application Discontinuation
- 2012-11-28 PH PH1/2012/000378A patent/PH12012000378A1/en unknown
- 2012-11-29 TN TNP2012000563A patent/TN2012000563A1/fr unknown
- 2012-11-29 SG SG2012087771A patent/SG191494A1/en unknown
- 2012-12-03 NI NI201200178A patent/NI201200178A/es unknown
- 2012-12-03 MA MA35425A patent/MA34867B1/fr unknown
- 2012-12-03 MD MDA20120119A patent/MD4348B1/ro not_active IP Right Cessation
- 2012-12-03 CR CR20120608A patent/CR20120608A/es unknown
- 2012-12-05 MX MX2012014184A patent/MX2012014184A/es not_active Application Discontinuation
- 2012-12-05 BR BR102012031031-7A patent/BR102012031031A2/pt not_active Application Discontinuation
- 2012-12-05 AP AP2012006607A patent/AP3225A/xx active
- 2012-12-06 JP JP2012267342A patent/JP5591310B2/ja not_active Expired - Fee Related
- 2012-12-06 CL CL2012003437A patent/CL2012003437A1/es unknown
- 2012-12-06 CO CO12221472A patent/CO6690116A1/es unknown
- 2012-12-06 TW TW101145875A patent/TWI457123B/zh not_active IP Right Cessation
- 2012-12-06 CA CA2798549A patent/CA2798549A1/fr not_active Abandoned
- 2012-12-06 KR KR20120141338A patent/KR101489670B1/ko not_active Expired - Fee Related
- 2012-12-06 US US13/706,828 patent/US8921409B2/en not_active Expired - Fee Related
- 2012-12-07 EC ECSP12012329 patent/ECSP12012329A/es unknown
- 2012-12-07 AR ARP120104595A patent/AR089112A1/es unknown
- 2012-12-07 GT GT201200329A patent/GT201200329A/es unknown
- 2012-12-07 WO PCT/FR2012/000505 patent/WO2013083887A1/fr not_active Ceased
- 2012-12-07 EP EP12195997.7A patent/EP2601942A1/fr not_active Withdrawn
- 2012-12-07 EA EA201201530A patent/EA201201530A1/ru unknown
- 2012-12-10 CN CN201210530112.9A patent/CN103157111B/zh not_active Expired - Fee Related
-
2014
- 2014-11-25 US US14/553,206 patent/US20150080448A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123365T1 (el) | Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα | |
| CY1116892T1 (el) | Ενωσεις οι οποιες εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
| UA112317C2 (uk) | Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину | |
| MX2014014710A (es) | Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar). | |
| PH12013502463A1 (en) | Trpv4 antagonists | |
| BR112015012746A2 (pt) | compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos | |
| GEP201606526B (en) | 5-ht3 receptor antagonists | |
| MX348933B (es) | Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico. | |
| NI201500080A (es) | Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3. | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| PE20130813A1 (es) | Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmaceuticas que la contienen | |
| EA201300857A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| NZ705813A (en) | Treatment of mild and moderate alzheimer’s disease | |
| EA201490573A1 (ru) | Соединение бензотиазолона | |
| NI201200102A (es) | Procedimiento de síntesis y forma cristalina del hidrocloruro de 4 - { 3 - [ cis - hexahidrociclopenta [c] pirrol - 2 (1h) - il ] propoxi } benzamida así como las composiciones farmacéuticas que la contienen. | |
| EA201692090A1 (ru) | Полициклические активаторы herg | |
| EA201391348A8 (ru) | КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА | |
| TN2015000058A1 (en) | Salts of benzothiazolone compound as beta-2-adrenoceptor agonist | |
| EA201300160A1 (ru) | 2,3,5-тризамещенные тиофены и их применение | |
| CU20120167A7 (es) | Nueva asociación entre la 4-{3-(cis-hexahidrociclopenta(c)pirrol-2(1h)-il)propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmacéuticas que la contienen | |
| UA109581C2 (uk) | Сполуки з активністю антагоністів мускаринових рецепторів і агоністів адренергічного рецептора бета2 | |
| TN2013000429A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| ECSP15026152A (es) | Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas beta2 adrenérgicos y como antagonistas muscarínicos m3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |